Search research articles
Contact Us
Filters
Showing results (81-90 of 99) with videos related to
Page
of 10
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 24, 2021
Molecular Subtyping Combined with Biological Pathway Analyses to Study Regorafenib Response in Clinically Relevant Mouse Models of Colorectal Cancer
Adam Lafferty, Alice C O'Farrell, Giorgia Migliardi, et al.
Cancer Discovery
|
June 5, 2013
Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer
Alberto Bardelli, Simona Corso, Andrea Bertotti, et al.
The Lancet. Oncology
|
April 25, 2016
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial
Andrea Sartore-Bianchi, Livio Trusolino, Cosimo Martino, et al.
Nature
|
February 24, 2022
Effective drug combinations in breast, colon and pancreatic cancer cells
Patricia Jaaks, Elizabeth A Coker, Daniel J Vis, et al.
Cancer Discovery
|
May 21, 2020
EGFR Blockade Reverts Resistance to KRAS<sup>G12C</sup> Inhibition in Colorectal Cancer
Vito Amodio, Rona Yaeger, Pamela Arcella, et al.
Science Translational Medicine
|
August 8, 2020
Colorectal cancer residual disease at maximal response to EGFR blockade displays a druggable Paneth cell-like phenotype
Barbara Lupo, Francesco Sassi, Marika Pinnelli, et al.
Neoplasia (New York, N.Y.)
|
March 26, 2018
Rituximab Treatment Prevents Lymphoma Onset in Gastric Cancer Patient-Derived Xenografts
Simona Corso, Marilisa Cargnelutti, Stefania Durando, et al.
Nature
|
September 30, 2015
The genomic landscape of response to EGFR blockade in colorectal cancer
Andrea Bertotti, Eniko Papp, Siân Jones, et al.
Cancer Discovery
|
September 22, 2025
The molecular and functional landscape of resistance to FOLFIRI chemotherapy in metastatic colorectal cancer
Marco Avolio, Simonetta M Leto, Francesco Sassi, et al.
Nature
|
February 16, 2026
Author Correction: The genomic landscape of response to EGFR blockade in colorectal cancer
Andrea Bertotti, Eniko Papp, Siân Jones, et al.
Page
of 10
Search research articles
Search
Showing results (81-90 of 99) with videos related to
Sort By:
Page
of 10
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 24, 2021
Molecular Subtyping Combined with Biological Pathway Analyses to Study Regorafenib Response in Clinically Relevant Mouse Models of Colorectal Cancer
Adam Lafferty, Alice C O'Farrell, Giorgia Migliardi, et al.
Cancer Discovery
|
June 5, 2013
Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer
Alberto Bardelli, Simona Corso, Andrea Bertotti, et al.
The Lancet. Oncology
|
April 25, 2016
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial
Andrea Sartore-Bianchi, Livio Trusolino, Cosimo Martino, et al.
Nature
|
February 24, 2022
Effective drug combinations in breast, colon and pancreatic cancer cells
Patricia Jaaks, Elizabeth A Coker, Daniel J Vis, et al.
Cancer Discovery
|
May 21, 2020
EGFR Blockade Reverts Resistance to KRAS<sup>G12C</sup> Inhibition in Colorectal Cancer
Vito Amodio, Rona Yaeger, Pamela Arcella, et al.
Science Translational Medicine
|
August 8, 2020
Colorectal cancer residual disease at maximal response to EGFR blockade displays a druggable Paneth cell-like phenotype
Barbara Lupo, Francesco Sassi, Marika Pinnelli, et al.
Neoplasia (New York, N.Y.)
|
March 26, 2018
Rituximab Treatment Prevents Lymphoma Onset in Gastric Cancer Patient-Derived Xenografts
Simona Corso, Marilisa Cargnelutti, Stefania Durando, et al.
Nature
|
September 30, 2015
The genomic landscape of response to EGFR blockade in colorectal cancer
Andrea Bertotti, Eniko Papp, Siân Jones, et al.
Cancer Discovery
|
September 22, 2025
The molecular and functional landscape of resistance to FOLFIRI chemotherapy in metastatic colorectal cancer
Marco Avolio, Simonetta M Leto, Francesco Sassi, et al.
Nature
|
February 16, 2026
Author Correction: The genomic landscape of response to EGFR blockade in colorectal cancer
Andrea Bertotti, Eniko Papp, Siân Jones, et al.
Page
of 10